Vandortuzumab Vedotin Biosimilar Antibody-Drug Conjugate (STEAP1) for Research
Pre-made Vandortuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-STEAP1 therapeutic antibody, Anti-PRSS24/STEAP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vandortuzumab vedotin (INN; development code RG745) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1044-1mg | 1mg | 4635 |
| GMP-Bios-INN-1044-10mg | 10mg | |
| GMP-Bios-INN-1044-100mg | 100mg | |
| GMP-Bios-INN-1044-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vandortuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Steap1 Antibody: Anti-PRSS24/STEAP therapeutic antibody Drug Conjugate |
| INN Name | Vandortuzumab Vedotin |
| Target | STEAP1 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - STEAP1
1. Protein Metalloreductase STEAP1
2. Gene STEAP1
3. Organism Homo sapiens (Human)
Function
Metalloreductase that has the ability to reduce both Fe3+ to Fe2+ and Cu2+ to Cu1+. Uses NAD+ as acceptor.
Cofactor
Protein has several cofactor binding sites:
FAD
heme

